Goodbye, Blue Sky: Shortcutting Discovery
Executive Summary
A handful of European biotechnology companies is embracing development shortcuts that were once the exclusive provenance of specialty pharmaceutical firms. Shedding traditional biotech start-up discovery models, these firms aim to identify, reformulate and incrementally improve existing products. The hope is that low risk needn't be low reward; in the process these so-called reprofilers of existing therapies may indeed spark an increase in industry productivity. The trick, observers say, is finding and getting their hands on the right products.
You may also be interested in...
Solvay Pharma: Dealing Its Way Into the Limelight
BMS and Wyeth are two of the latest to have noticed Solvay’s unusually healthy pipeline. The mid-sized group’s new dealmaking drive means they’re unlikely to be the last.
Exploiting Connections and Navigating Bumps Along the Brain-Gut Axis
The recent setback in SUI by Lilly's depression drug duloxetine may have implcations for a handful of biotech companies aiming to exploit their knowledge of the brain-gut axis to develop CNS drugs for IBS, OAB and other below-the-belt indications. Dynogen and Vela are two companies with promising products in the area.
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Bayer's retreat from the global, primary-care stage into the mid-sized, regionally-focused specialist player arena was forced upon it by its own particular set of challenges. But other drug firms facing similar issues should take note: globalism may not be the best way forward in today's environment.